Ovid Therapeutics Inc. (OVID)
NasdaqCM · USD · Healthcare · Biotechnology
$2.16 (-0.23%) as of
Key statistics
- Market cap
- 420.87M
- Forward P/E
- -5.88
- EPS (TTM)
- -0.2200
- Dividend yield
- 0.00%
- 52-week range
- 1.1800 – 3.1050
- Beta
- 0.23
- Revenue (TTM)
- 1.58M
- Profit margin
- 0.00%
- Analyst target
- $6.00
- Volume
- 843.86k
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 23
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.